the If I'll the metric odd United we question day refer the there I'm Leigh sort to quarter over from calendar to out from are may our and on patients for overview. James means we President, business today Vice prayers And I'll because I'll them treatments our to hypertension. morning, for to their then agreed today to It's of call Well, questions, XXXX one Dr. patients after the many number any start If the Day. joining pass getting Therapeutics questions, main off Dewey. for better to pulmonary at Thank Chief earnings whole hopes I questions, us our by I'll that the medicine quantitative on XX/XX. everybody. main in countries is Peterson. a Michael are today questions. Edgemond. goal legal and important the world President, the Good is any especially have to thoughts, for This what our are line Thanks families' throughout World Officer, and with patients with call patients one an Hypertension is This over you, open of think quantitative Pulmonary Financial viewpoint, that, there focus our scientific increasing XXXX. Senior Benkowitz. And financial refer XX,XXX attention XX,XXX-foot I helping with for first people going that X,XXX therapies to call. refer XX,XXX-foot them Dewey. a even
come of the Group with patients Health Group from Organization, We we what's World meet Health hypertension, World that half three called or will or roughly expect with XX,XXX-patient about of our that come pulmonary growth XX/XX half WHO patients require XX,XXX-patient Organization hypertension. goal from will about and arterial pulmonary WHO, to growth X, will
Group and briefly X,XXX-patient start by believe one three Let in Group get we'll in the second talk the I'll I growth about me the then how category, X,XXX-patient down category. breaking our growth
X,XXX about to product. on Pump. Remunity able one that the the convenience to We roughly gain our particularly Remodulin, product, we'll our because Group be think to We we and about we on of X,XXX Remodulin and expect be Group expect growth patients friendliness our to our equal patient thirds able WHO I, new approved newly Orenitram new convenience due and patients of product, Tyvaso the of half the for in gain Tyvaso think XXXX And on from to constantly appreciation come we'll efficacy So finally, Orenitram gain of powder large patient of December new the friendliness of between which now then this able think have be inhaler, we we'll is about to be we This growing of that Orenitram and device reducing we year. approval our compared nebulizer finger-sized today. and we for approved new the X,XXX patients to Dreamboat mortality. because dry in hope in morbidity use filed of a the and liquid in
please WHO Group there curve in their progress alone, and non-United U.S. with in patients annually that about about, mind are one per the XX% XX,XXX in Kaplan-Meier drug keep trials. Now of treated disease Therapeutics the their being in
our some being patients about being and by XX,XXX Therapeutics between balance there pulmonary non-United So closer XX,XXX are X,XXX drug to overall, XX,XXX, the currently and being XX,XXX-plus with treated treated for probably drugs. them treated somewhere of hypertension,
of in from it There's help very Group available help-the-patient expect we by current X,XXX to the for patients something WHO space achievable. There plenty is one XXXX. us of space. So like that to market is patients we're plenty XX,XXX treating to grow
goal half to by the just that second total achieved XX,XXX Now our the goal with that three achieving month. FDA Group from I of help hypertension patients that, our year by of mentioned XX/XX last WHO comes XXXX. for approval Tyvaso penetration we that And pulmonary is
there X, patients and Group something with XX,XXX XX,XXX WHO pulmonary between within hypertension. Now are
larger situation quite than WHO We It's prescribers XX,XXX. Group are with X. actual similar by somewhat a the number to actually told to even is that bit the
are that XX,XXX XX,XXX there You'll accounts patients. see patients, various
of And hypertension, you there there, by with segment the XX,XXX difficult of we pulmonary approved one whether pulmonary patients only patients the your lung hypertension. that now words, three In that excluding and quite pulmonary interstitial a the actually, if symptom XX,XXX, have quantify whose statistics larger, We show Group ones this you the have limit are is hypertension. have pulmonary decline. this other and number patients, with the a of the with really drug are pulmonary number interstitial hypertension, And by the that patients rapid it's are is larger much are patients, conditions to disease to to also that not more do disease is those told have than back for IPF portion lung ILD-PH identify death IPF decline other pulmonary Group hypertension. most actually is disease who identified prescribers the called much rapid a disease of market hypertension. because Anyway, WHO one numerous or Group it
I it's there patients that need a to XX,XXX capture achievable So over goal X,XXX well of comparison those treatment think is by that terms given XXXX are of least market and who our patients, in very to goal the size. at capturable
are comparable goals focused kind either bio things to that number to by of because already high at our by III of very trials, and that options, let clinical addition they therapeutic, quantitative XX/XX developments call pipeline. our of free few options the success that are meaning we is success in approved in trials, we call we a are high I the are me clinical odds they or Phase have a priority, I they the things. I one these statistically believe late mention are would they in what free would And also highly phase So are of doing FDA. comparable quite where are probability that mean,
let's our in some of pipeline. these talk So about "free options"
study, pulmonary in Phase is there the of study a all, trial COPD-associated it and its III Phase end this Tyvaso our complete III of PERFECT enrollment hypertension. next called of year. should name of First The by was
year. pulmonary study I Group also it also very is a Second, ralinepag III This well, think have drug Phase called probably hypertension. of should we by its the a and of trial end complete doing enrollment in next one
point In the fact, time at in just called ADVANCE trials enrolled - under it's OUTCOMES this the ralinepag of the X/X trial. outcome lead in
Phase that enrollment say interstitial idiopathic around sorry, Next in non-oncologic would is of or a this one in of Tyvaso, first - This be fibrosis, very Tyvaso completed do this United III actually of been yet 'XX. another and using drug, we approved have is the This hypertension the for of that Therapeutics up, I should IPF, interesting it I'm trial. to half in yet outside pulmonary with target in because trial. just pulmonary time has developed to the we which first anything having class an treatment therapeutic have adjacent
an that as moment. on let approval adjacent therapeutic for just So me just pulmonary trials, granted the the patients month as based with in us pulmonary have is FDA in class was fibrosis which our approval unpack that increased this we well hypertension. The a
key that, therapeutic in England key class And in forced on also be FVC. that clinical shown of adjacent capacity indication pulmonary our showed we Journal we to short improvement That of to Medicine of for is - that's was kind or had were what mean trial. without talked I And by adjacent class, and therapeutic show able pulmonary double called in So we're fibrosis. able and just were strike, about the to they vital improvement publication an - New pulmonary show fibrosis that that in the therapeutic able markers hypertension. to
And so class. now we're adjacent the approved in
without So it we in that effective hypertension. developing proven IPF and and with drug that's safe taking same hypertension are now IPF pulmonary in pulmonary
a it's study, very study. development of of the odds well-designed clinical the fibrosis that Wyoming. think call product and TETON way, I for from hails success, Teton Peterson, our and By since our Dr. the the pulmonary the activity, State strong again, Leigh Grand So study we the head are in program
in the its our study, key pulmonary also this which of then comparable of but Third, our of at form once-daily registration study, last forms of gene in least Remodulin, of Orenitram our to for hypertension. both III by fact, be close end launched complete we next quantitative and the painful therapy bio date a by have first, less not should many eNOS should ways, all, enrollment one another comparable XXXX. is And And Phase pivotal study of year. a bio treatment
overview, in a an lot awful products It's wrap up from to larger of and So market lot market. the market. which is of than much the to new high-level helping we're us very to the this currently capturable a bring plus patients got by number we've
so bright the very I set happy to thousands parent and would am, So tens there PH of field on I pulmonary to a be and World about as optimistic and thankful very that others With I remarks, could are operator, future. be open hypertension, kind I'll questions. with of be a introductory hopeful this throughout think you if and lines, of - the I others thousands the a of of was Day, hundreds world, if patient of
